The role of SARS-CoV-2 spike protein in growth of cervical cancer cells

Abstract

Abstract Background: Recently developed vaccines for the SARS-CoV-2 virus utilize endogenous production of the virus’ spike protein (SP), allowing the host to develop an immune response. As a result of the novelty of this virus and its vaccines, little is known overall about the potential effects of the SP on the pathogenesis of neoplasia, either from vaccination or from infection. This study was designed to investigate if SARS-CoV-2 SP has any direct effect on SiHa cervical cancer cells. Methods: The effects of SARS-CoV-2 SP on cervical cancer cell proliferation and apoptosis were investigated by using clonogenic cell survival assay, quick cell proliferation assay, and caspase-3 activity kits in a widely used cervical cancer cell line, SiHa. RT-PCR and immunohistochemistry were also performed to determine the potential molecular mechanisms. Results: The growth and proliferation of SiHa cancer cells were inhibited by SARS-CoV-2 SP. SARS-CoV-2 SP also induced apoptosis in SiHa cancer cells. The anti-proliferative effect of SARS-CoV-2 SP on SiHa cancer cells was associated with the upregulation of the anti-proliferative molecule p53. The pro-apoptotic effect of SARS-CoV-2 SP on SiHa cells was associated with the upregulation of the pro-apoptotic molecule TRAIL. Conclusion: SARS-CoV-2 SP inhibits the growth of cervical cancer via upregulation of p53 and TRAIL. Further studies are needed to elaborate on the potential effects of the SARS-CoV-2 SP on other cancer cell lines and other normal physiological cell lines to compare.